{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:21:19Z","timestamp":1777954879571,"version":"3.51.4"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Renin-angiotensin system inhibitors (RASIs) have been reported to exert anticancer effects. However, there is still a lack of persuasive evidence for their role in improving postoperative long-term oncologic outcomes of colorectal cancer. This retrospective cohort study emulated a hypothetical randomized controlled trial to evaluate the efficacy of RASIs in improving postoperative long-term oncologic outcomes of patients with stage II\/III colon cancer and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients were consecutively enrolled from multicenter databases, which contained data from medical centers in Shanghai, China. Eligible criteria were adults with radical resected stage II or III colon adenocarcinoma and hypertension. Eligible patients were classified into the RASI group or the no-RASI group, and propensity score was matched at a 1:1 ratio. The primary outcome was the 3-year disease-free survival (DFS) rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      From 2,640 eligible patients, 2,292 were included in the primary analysis after matching: 1,146 in the RASI group and 1,146 in the no-RASI group. The median follow-up time was 46.3 months. The RASI group had a higher 3-year DFS rate (83.4%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      78.3%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001; hazard ratio [HR], 0.736 [95% CI, 0.617 to 0.878]). The RASI group also had a lower 3-year distant metastasis rate (15.6%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      20.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001; HR, 0.717 [95% CI, 0.596 to 0.863]) and a higher 3-year overall survival rate (92.4%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      89.6%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001; HR, 0.682 [95% CI, 0.539 to 0.864]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>RASIs may improve the postoperative long-term oncologic outcomes for patients with stage II\/III colon cancer and hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-01296","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:59:21Z","timestamp":1777924761000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II\/III Colon Cancer and Hypertension: A Target Trial Emulation"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct07012538","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0553-6038","authenticated-orcid":true,"given":"Kaiwen","family":"Chen","sequence":"first","affiliation":[{"name":"Colorectal Surgery Department, Zhongshan Hospital Fudan University, Shanghai, China"},{"name":"Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-0960","authenticated-orcid":true,"given":"Donghao","family":"Xu","sequence":"additional","affiliation":[{"name":"Colorectal Surgery Department, Zhongshan Hospital Fudan University, Shanghai, China"},{"name":"Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Colorectal Surgery Department, Zhongshan Hospital Fudan University, Shanghai, China"},{"name":"Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-7844","authenticated-orcid":true,"given":"Fei","family":"Liang","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"He","sequence":"additional","affiliation":[{"name":"Colorectal Surgery Department, Zhongshan Hospital Fudan University, Shanghai, China"},{"name":"Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-8240","authenticated-orcid":true,"given":"Jianmin","family":"Xu","sequence":"additional","affiliation":[{"name":"Colorectal Surgery Department, Zhongshan Hospital Fudan University, Shanghai, China"},{"name":"Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-9301","authenticated-orcid":true,"given":"Qingyang","family":"Feng","sequence":"additional","affiliation":[{"name":"Colorectal Surgery Department, Zhongshan Hospital Fudan University, Shanghai, China"},{"name":"Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4238"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713709"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30527-1"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01330"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031389"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5616"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2945"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.05.005"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2332"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155104"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6527457"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30079"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-28"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.09.001"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4088"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwz106"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09919-0"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_9_22_2","first-page":"1","article-title":"The guidelines for prevention and control of overweight and obesity in Chinese adults","volume":"17","author":"Chen C","year":"2004","unstructured":"Chen C, Lu FC, Department of Disease Control Ministry of Health, PR China: The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci 17:1-36, 2004 (suppl)","journal-title":"Biomed Environ Sci"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.26599\/1671-5411.2025.01.008"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12639"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073435"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq198"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.37737\/ace.22013"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111338"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1515\/ijb-2012-0030"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001302"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0375"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00393"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3516"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3653"},{"key":"e_1_3_9_37_2","first-page":"1073","article-title":"The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor","volume":"7","author":"Yoshiji H","year":"2001","unstructured":"Yoshiji H, Kuriyama S, Kawata M, et al: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073-1078, 2001","journal-title":"Clin Cancer Res"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.10.015"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000487"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-01296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:59:22Z","timestamp":1777924762000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-01296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":38,"alternative-id":["10.1200\/OP-25-01296"],"URL":"https:\/\/doi.org\/10.1200\/op-25-01296","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"2025-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-01296"}}